Mavorixafor Disrupts the Crosstalk Between Waldenström’s Macroglobulinemia Cells and the Bone Marrow Microenvironment Resulting in Enhanced Sensitivity to B-Cell–Targeted Therapies


X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.